MMP9 and respiratory syncytial virus infectious disease: Previous studies have observed that type I IFNs inhibit TNF-α-dependent MMP-9 activation in tumour cell lines, and IFN therapy can suppress MMP expression in tumour models and during respiratory syncytial virus infection in mice [61–63].